Total Payments
$42,465
2024 Payments
$427.58
Companies
12
Transactions
289
Medicare Patients
642
Medicare Billing
$57,232
Payment Breakdown by Category
Other$34,488 (81.2%)
Food & Beverage$7,022 (16.5%)
Travel$895.11 (2.1%)
Education$60.83 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,488 | 26 | 81.2% |
| Food and Beverage | $7,022 | 258 | 16.5% |
| Travel and Lodging | $895.11 | 2 | 2.1% |
| Education | $60.83 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $24,513 | 36 | $0 (2024) |
| Allergan Inc. | $9,766 | 23 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $4,953 | 138 | $0 (2022) |
| ABBVIE INC. | $1,097 | 33 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $916.00 | 23 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $529.26 | 20 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $262.51 | 4 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $123.58 | 1 | $0 (2018) |
| Lundbeck LLC | $122.84 | 8 | $0 (2020) |
| Indivior Inc. | $113.81 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $427.58 | 13 | ABBVIE INC. ($248.26) |
| 2023 | $3,476 | 17 | Alkermes, Inc. ($3,074) |
| 2022 | $6,520 | 42 | Alkermes, Inc. ($5,489) |
| 2021 | $11,581 | 25 | Alkermes, Inc. ($10,517) |
| 2020 | $5,698 | 32 | Alkermes, Inc. ($4,860) |
| 2019 | $3,496 | 55 | Sunovion Pharmaceuticals Inc. ($2,325) |
| 2018 | $890.63 | 38 | Sunovion Pharmaceuticals Inc. ($274.32) |
| 2017 | $10,377 | 67 | Allergan Inc. ($9,598) |
All Payment Transactions
289 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $108.20 | General |
| Category: Neuropsychiatry | ||||||
| 10/01/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.23 | General |
| Category: NEUROSCIENCE | ||||||
| 05/01/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: NEUROSCIENCE | ||||||
| 04/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.07 | General |
| Category: NEUROSCIENCE | ||||||
| 03/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: NEUROSCIENCE | ||||||
| 02/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: NEUROSCIENCE | ||||||
| 02/20/2024 | Janssen Pharmaceuticals, Inc | INVEGA (Drug) | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Neuroscience | ||||||
| 02/13/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: PSYCHIATRY | ||||||
| 01/31/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.39 | General |
| Category: NEUROSCIENCE | ||||||
| 01/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.19 | General |
| Category: NEUROSCIENCE | ||||||
| 01/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.80 | General |
| Category: NEUROSCIENCE | ||||||
| 01/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $34.45 | General |
| Category: NEUROSCIENCE | ||||||
| 01/10/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: CNS | ||||||
| 11/20/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.05 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $125.01 | General |
| Category: NEUROSCIENCE | ||||||
| 10/26/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: CNS | ||||||
| 10/18/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.86 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.37 | General |
| Category: NEUROSCIENCE | ||||||
| 07/26/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.19 | General |
| Category: NEUROSCIENCE | ||||||
| 06/27/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: CNS | ||||||
| 06/15/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: NEUROSCIENCE | ||||||
| 06/08/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $31.32 | General |
| Category: NEUROSCIENCE | ||||||
| 05/18/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: NEUROSCIENCE | ||||||
| 05/03/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: CNS | ||||||
| 04/18/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.95 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 122 | 318 | $35,231 | $10,510 |
| 2022 | 3 | 118 | 310 | $29,466 | $10,133 |
| 2021 | 4 | 144 | 383 | $37,310 | $15,038 |
| 2020 | 7 | 258 | 602 | $61,275 | $21,551 |
Total Patients
642
Total Services
1,613
Medicare Billing
$57,232
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 39 | 90 | $12,395 | $5,104 | 41.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 44 | 111 | $12,163 | $3,999 | 32.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 28 | 104 | $8,983 | $765.38 | 8.5% |
| 90832 | Psychotherapy, 30 minutes | Office | 2023 | 11 | 13 | $1,689 | $641.85 | 38.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 44 | 99 | $12,820 | $5,397 | 42.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 51 | 119 | $9,282 | $4,060 | 43.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 23 | 92 | $7,364 | $676.12 | 9.2% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 66 | 169 | $13,182 | $6,397 | 48.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 43 | 98 | $12,969 | $6,335 | 48.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 17 | $3,201 | $1,479 | 46.2% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 20 | 99 | $7,958 | $826.96 | 10.4% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 113 | 326 | $25,359 | $9,604 | 37.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 47 | 98 | $12,826 | $4,809 | 37.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 32 | 40 | $7,868 | $3,105 | 39.5% |
| 90834 | Psychotherapy, 45 minutes | Office | 2020 | 19 | 21 | $3,367 | $1,122 | 33.3% |
| 90832 | Psychotherapy, 30 minutes | Office | 2020 | 17 | 22 | $2,640 | $1,086 | 41.1% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 13 | 13 | $2,600 | $1,081 | 41.6% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 17 | 82 | $6,615 | $744.50 | 11.3% |
About Dr. Gerard Lippert, MD
Dr. Gerard Lippert, MD is a Pain Medicine healthcare provider based in Ithaca, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013955152.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gerard Lippert, MD has received a total of $42,465 in payments from pharmaceutical and medical device companies, with $427.58 received in 2024. These payments were reported across 289 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($34,488).
As a Medicare-enrolled provider, Lippert has provided services to 642 Medicare beneficiaries, totaling 1,613 services with total Medicare billing of $57,232. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Pain Medicine
- Other Specialties Psychiatry
- Location Ithaca, NY
- Active Since 06/02/2006
- Last Updated 02/13/2008
- Taxonomy Code 2084P2900X
- Entity Type Individual
- NPI Number 1013955152
Products in Payments
- ARISTADA (Drug) $24,189
- VRAYLAR (Drug) $10,863
- LATUDA (Drug) $4,953
- REXULTI (Drug) $659.99
- ABILIFY MAINTENA (Drug) $378.85
- INGREZZA (Drug) $262.51
- INVEGA SUSTENNA (Drug) $231.82
- LYBALVI (Drug) $213.87
- SPRAVATO (Drug) $198.27
- AUSTEDO (Drug) $123.58
- SUBLOCADE (Drug) $113.81
- Aristada 441 mg (Drug) $109.23
- INVEGA TRINZA (Drug) $76.12
- CAPLYTA (Drug) $46.91
- INVEGA (Drug) $23.05
- TRINTELLIX (Drug) $20.69
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.